FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315753604> ?p ?o ?g. }

• W4315753604 endingPage "230" @default.
• W4315753604 startingPage "223" @default.
• W4315753604 abstract "Objective Gynecological sarcomas account for 3% of all gynecological malignancies and are associated with a poor prognosis. Due to the rarity and heterogeneity of gynecological sarcomas there is still no consensus on optimal therapeutic strategies. This study’s objective was to describe the treatment strategies used in patients with gynecological sarcomas in the primary course of disease. Methods The German prospective registry for gynecological sarcoma (REGSA) is the largest registry for gynecological sarcomas in Germany, Austria and Switzerland. Primary inclusion criteria for REGSA are histological diagnosis of sarcoma of the female genital tract, sarcoma of the breast or uterine smooth muscle tumors of uncertain malignant potential (STUMP). We evaluated data of the REGSA registry on therapeutic strategies used for primary treatment from August 2015 to February 2021. Results A total of 723 patients from 120 centers were included. Data on therapeutic strategies for primary treatment were available in 605 cases. Overall, 580 (95.9%) patients underwent primary surgery, 472 (81.4%) of whom underwent only hysterectomy. Morcellation was reported in 11.4% (n=54) of all hysterectomies. A total of 42.8% (n=202) had no further surgical interventions, whereas an additional salpingo-ophorectomy was performed in 54% (n=255) of patients. An additional lymphadenectomy was performed in 12.7% (n=60), an omentectomy in 9.5% (n=45) and intestinal resection in 6.1% (n=29) of all patients. Among 448 patients with available information, 21.4% (n=96) received chemo- or targeted therapies, more commonly as single-agent treatment than as drug combinations. Information about anti-hormonal treatment was available for 423 patients, among which 42 (9.9%) received anti-hormonal treatment, 23 (54.8%) of whom with low-grade endometrial stroma sarcomas. For radiotherapy, data of 437 patients were available, among which 29 (6.6%) patients underwent radiotherapy. Conclusion Our study showed that treatment of patients with gynecologic sarcomas is heterogeneous. Further trials are needed along with more information on treatment modalities, therapy response and patient-reported outcomes to implement new treatment strategies." @default.
• W4315753604 created "2023-01-13" @default.
• W4315753604 creator A5002555374 @default.
• W4315753604 creator A5007265273 @default.
• W4315753604 creator A5008883508 @default.
• W4315753604 creator A5010971321 @default.
• W4315753604 creator A5011353416 @default.
• W4315753604 creator A5020357121 @default.
• W4315753604 creator A5020736525 @default.
• W4315753604 creator A5020958701 @default.
• W4315753604 creator A5021413572 @default.
• W4315753604 creator A5021528284 @default.
• W4315753604 creator A5021788007 @default.
• W4315753604 creator A5022300936 @default.
• W4315753604 creator A5023008141 @default.
• W4315753604 creator A5025215479 @default.
• W4315753604 creator A5026364343 @default.
• W4315753604 creator A5029842350 @default.
• W4315753604 creator A5030837961 @default.
• W4315753604 creator A5034695241 @default.
• W4315753604 creator A5035187130 @default.
• W4315753604 creator A5037682627 @default.
• W4315753604 creator A5048121068 @default.
• W4315753604 creator A5050467390 @default.
• W4315753604 creator A5061545433 @default.
• W4315753604 creator A5063215428 @default.
• W4315753604 creator A5064559513 @default.
• W4315753604 creator A5066640097 @default.
• W4315753604 creator A5068115141 @default.
• W4315753604 creator A5068601323 @default.
• W4315753604 creator A5070971918 @default.
• W4315753604 creator A5072861257 @default.
• W4315753604 creator A5073580516 @default.
• W4315753604 creator A5075379768 @default.
• W4315753604 creator A5078567055 @default.
• W4315753604 creator A5078861711 @default.
• W4315753604 creator A5081947837 @default.
• W4315753604 creator A5083149859 @default.
• W4315753604 creator A5088082888 @default.
• W4315753604 creator A5089452970 @default.
• W4315753604 creator A5090196961 @default.
• W4315753604 creator A5090489400 @default.
• W4315753604 date "2023-01-11" @default.
• W4315753604 modified "2023-10-18" @default.
• W4315753604 title "Treatment strategies in patients with gynecological sarcoma: Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA-NOGGO RU1)" @default.
• W4315753604 cites W1502045029 @default.
• W4315753604 cites W1528500075 @default.
• W4315753604 cites W1966267146 @default.
• W4315753604 cites W2004001144 @default.
• W4315753604 cites W2030590505 @default.
• W4315753604 cites W2033329597 @default.
• W4315753604 cites W2047422980 @default.
• W4315753604 cites W2055063099 @default.
• W4315753604 cites W2060254819 @default.
• W4315753604 cites W2064136894 @default.
• W4315753604 cites W2069693587 @default.
• W4315753604 cites W2071123235 @default.
• W4315753604 cites W2091789196 @default.
• W4315753604 cites W2098553441 @default.
• W4315753604 cites W2116025938 @default.
• W4315753604 cites W2129429170 @default.
• W4315753604 cites W2140292293 @default.
• W4315753604 cites W2140377151 @default.
• W4315753604 cites W2170281817 @default.
• W4315753604 cites W2177805364 @default.
• W4315753604 cites W2222024717 @default.
• W4315753604 cites W2236777922 @default.
• W4315753604 cites W2332208369 @default.
• W4315753604 cites W2488456052 @default.
• W4315753604 cites W2547843406 @default.
• W4315753604 cites W2588395027 @default.
• W4315753604 cites W2603796533 @default.
• W4315753604 cites W2752560124 @default.
• W4315753604 cites W2765603843 @default.
• W4315753604 cites W2984796643 @default.
• W4315753604 cites W2990427812 @default.
• W4315753604 cites W3203101078 @default.
• W4315753604 doi "https://doi.org/10.1136/ijgc-2022-003800" @default.
• W4315753604 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36631151" @default.
• W4315753604 hasPublicationYear "2023" @default.
• W4315753604 type Work @default.
• W4315753604 citedByCount "0" @default.
• W4315753604 crossrefType "journal-article" @default.
• W4315753604 hasAuthorship W4315753604A5002555374 @default.
• W4315753604 hasAuthorship W4315753604A5007265273 @default.
• W4315753604 hasAuthorship W4315753604A5008883508 @default.
• W4315753604 hasAuthorship W4315753604A5010971321 @default.
• W4315753604 hasAuthorship W4315753604A5011353416 @default.
• W4315753604 hasAuthorship W4315753604A5020357121 @default.
• W4315753604 hasAuthorship W4315753604A5020736525 @default.
• W4315753604 hasAuthorship W4315753604A5020958701 @default.
• W4315753604 hasAuthorship W4315753604A5021413572 @default.
• W4315753604 hasAuthorship W4315753604A5021528284 @default.
• W4315753604 hasAuthorship W4315753604A5021788007 @default.
• W4315753604 hasAuthorship W4315753604A5022300936 @default.
• W4315753604 hasAuthorship W4315753604A5023008141 @default.
• W4315753604 hasAuthorship W4315753604A5025215479 @default.
• W4315753604 hasAuthorship W4315753604A5026364343 @default.

• next